Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in the substantia nigra and the development of both motor manifestations (bradykinesia, rigidity, resting tremor) and non-motor symptoms. In recent years, particular attention has been devoted to the systemic complications of PD, among which disorders of bone and mineral metabolism occupy a significant place, substantially worsening patients’ quality of life and increasing the risk of disability. It has been established that patients with PD are significantly more likely to develop osteopenia and osteoporosis, accompanied by decreased bone mineral density and an increased risk of fractures, particularly in the proximal femur. One of the key contributing factors is Vitamin D deficiency, caused by reduced sunlight exposure, limited physical activity, and age-related metabolic changes. Additional contributing factors include disturbances in calcium-phosphorus homeostasis, sarcopenia, as well as alterations in hormonal status, including an imbalance of parathyroid hormone and calcitonin. The pathogenesis of bone disorders in PD is multifactorial. Hypodynamia and postural instability contribute to reduced mechanical loading on bone, leading to suppressed osteogenesis. Neurodegenerative processes and dopamine deficiency may directly influence bone metabolism through neuroendocrine mechanisms. Furthermore, long-term pharmacological therapy, particularly levodopa-based medications, may indirectly affect bone metabolism and homocysteine levels, which are also associated with an increased risk of fractures. Clinically, disorders of bone and mineral metabolism in PD are manifested by decreased bone mineral density, an increased frequency of falls and fractures, as well as delayed recovery following injuries. Diagnostic approaches include densitometry and assessment of Vitamin D, calcium, phosphorus levels, and markers of bone remodeling. Current approaches to management include comprehensive therapy aimed at correcting deficiencies of Vitamin D and calcium, the use of antiresorptive agents, optimization of physical activity, and fall prevention. Promising directions include personalized treatment strategies considering the stage of PD, the patient’s age, and concomitant risk factors, as well as the integration of a multidisciplinary approach involving neurologists, endocrinologists, and rehabilitation specialists. Disorders of bone and mineral metabolism represent an important component of the systemic manifestations of Parkinson’s disease and require timely diagnosis and comprehensive management to reduce fracture risk and improve patients’ quality of life.
| Mualliflar | Раҳимбаева Гулнора Саттаровна, Караманова Шаҳноза Зафар қизи |
|---|---|
| Jurnal | Журнал неврологии и нейрохирургических исследований / Journal of Neurology and Neurosurgical Research |
| Nashr sanasi | 2026-06-22 |
| Jild | 7 |
| Son | 4 |
| Til | Rus |
болезнь Паркинсона; костно-минеральный обмен; остеопороз; остеопения; витамин D; кальций-фосфорный обмен; переломы; дофамин; костная плотность; денситометрия; гиподинамия; саркопения; гомоцистеин; физическая реабилитация; профилактика остеопороза, Parkinson’s disease; bone and mineral metabolism; osteoporosis; osteopenia; Vitamin D; calcium-phosphorus metabolism; fractures; dopamine; bone mineral density; densitometry; hypodynamia; sarcopenia; homocysteine; physical rehabilitation; osteoporosis prevention, Паркинсон касаллиги; суяк-минерал алмашинуви; остеопороз; остеопения; D витамини; кальций-фосфор алмашинуви; синишлар; дофамин; суяк минерал зичлиги; денситометрия; гиподинамия; саркопения; гомоцистеин; жисмоний реабилитация; остеопороз профилактикаси
62 patients with CKD were examined, 22 of them with CKD stage I-II, 20 with CKD stage III, 20 with CKD stage IV. A questionnaire was conducted to identify limitations in daily activity, neuropsychological testing was…
The cognitive functions of the brain allow you to know the world, analyze information and make inferences. Cognitive impairment is one of the most disabling complications of ischemic stroke, significantly worsening the…
Combined malonic and methylmalonic aciduria (CMAMMA) is a rare inherited metabolic disorder caused by mutations in the ACSF3 gene. The disease is characterized by neurological impairment, developmental delay, epileptic…
The article presents the results of a study on psychoemotional disorders and the characteristics of micronutrient status in athletes with different levels of internet addiction. The study involved 96 athletes aged…
Biomarkers of the acute phase of hemorrhagic stroke are objective biochemical parameters that reflect the intensity of pathophysiological processes in the early days of the disease and have the potential to predict…
Objective: To evaluate the effectiveness of a personalized prevention strategy for recurrent hemorrhagic stroke in primary healthcare settings. Materials and methods: A prospective controlled study was conducted…
Stroke is one of the leading causes of death and disability worldwide, with the greatest burden falling on low- and middle-income countries. Tashkent lacks a unified stroke registry, and incidence statistics from…
Degenerative cervical myelopathy (DCM) is the most common cause of spinal cord compression and its subsequent degeneration in adults. Despite the fact that surgical decompression is the main method of treatment for…
To evaluate the specific characteristics of electromyographic parameters in patients with progressive muscular dystrophies (PMD) and determine their diagnostic and prognostic significance. Materials and Methods: Between…
A prospective comparative clinical study included 120 patients who underwent microdiscectomy or endoscopic discectomy for L4–L5 and L5–S1 disc herniations. Patients were divided into two groups: a standard…